Hepatitis C virus infection and the brain

Metabolic Brain Disease

Volumn 19, Issue 3-4, 2004, Pages 351-356

  Tillmann, Hans L ^a  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

brain; Hepatitis C; liver; natural history

Indexed keywords

ALPHA INTERFERON; AMANTADINE; LEPTIN; LIVER ENZYME; PEGINTERFERON; RIBAVIRIN;

BRAIN; BRAIN DISEASE; CONFERENCE PAPER; DNA VIRUS; ENCEPHALITIS; FLAVIVIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER FAILURE; NONHUMAN; PERSISTENT VIRUS INFECTION; RNA VIRUS;

ENCEPHALITIS, VIRAL; FATIGUE SYNDROME, CHRONIC; FLAVIVIRIDAE INFECTIONS; GB VIRUS C; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; PHYLOGENY;

DNA VIRUSES; FLAVIVIRIDAE; FLAVIVIRUS; GB VIRUS C/HEPATITIS G VIRUS; HEPATITIS C VIRUS; RNA VIRUSES;

EID: 5444266091     PISSN: 08857490     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:MEBR.0000043981.89134.39     Document Type: Conference Paper

References (29)

1. Alter, H.J., Purcell, R.H., Shih, J.W., Melpolder, J.C., Houghton, M., Choo, Q.L., and Kuo, G. (1989). Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N. Engl. J. Med. 321:1494-1500.
2. Alter, M.J., Margolis, H.S., Krawczynski, K., Judson, F.N., Mares, A., Alexander, W.J., Hu, P.Y., Miller, J.K., Gerber, M.A., Sampliner, R.E., et al. (1992). The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N. Engl. J. Med. 327:1899-1905.
3. Berg, T., Kronenberger, B., Hinrichsen, H., Gerlach, T., Buggisch, P., Herrmann, E., Spengler, U., Goeser, T., Nasser, S., Wursthorn, K., Pape, G.R., Hopf, U., and Zeuzem, S. (2003). Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: A placebo-controlled trial. Hepatology 37:1359-1367.
4. Bernstein, D., Kleinman, L., Barker, C.M., Revicki, D.A., and Green, J. (2002). Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 35:704-708.
5. Choo, Q.L., Kuo, G., Weiner, A.J., Overby, L.R., Bradley, D.W., and Houghton, M. (1989). Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244:359-362.
6. Fried, M.W., Shiffman, M.L., Reddy, K.R., Smith, C., Marinos, G., Goncales, F.L., Jr., Haussinger, D., Diago, M., Carosi, G., Dhumeaux, D., Craxi, A., Lin, A., Hoffman, J., and Yu, J. (2002). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347:975-982.
7. Goutagny, N., Fatmi, A., De Ledinghen, V., Penin, F., Couzigou, P., Inchauspe, G., and Bain, C. (2003). Evidence of viral replication in circulating dendritic cells during hepatitis C virus infection. J. Infect. Dis. 187:1951-1958.
8. Griffin, D.E., Levine, B., Tyor, W.R., and Irani, D.N. (1992). The immune response in viral encephalitis. Semin. Immunol. 4:111-119.
9. Kenny-Walsh, E. (1999). Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N. Engl. J. Med. 340:1228-1233.
10. Lau, D.T., Kleiner, D.E., Ghany, M.G., Park, Y., Schmid, P., and Hoofnagle, J.H. (1998). 10-year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology 28:1121-1127.
11. Lauer, G., and Walker, B. (2001). Hepatitis C virus. N. Engl. J. Med. 345:41-52.
12. Lindenbach, B.D., and Rice, C.M. (2002). Flaviviridae: The viruses and their replication. In Flieds Virology, pp. 991-1041.
13. Manns, M.P., McHutchison, J.G., Gordon, S.C., Rustgi, V.K., Shiffman, M., Reindollar, R., Goodman, Z.D., Koury, K., Ling, M., and Albrecht, J.K. (2001). Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet 358:958-965.
14. McHutchison, J.G., Gordon, S.C., Schiff, E.R., Shiftman, M.L., Lee, W.M., Rustgi, V.K., Goodman, Z.D., Ling, M.H., Cort, S., and Albrecht, J.K. (1998). Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 339:1485-1492.
15. Pawlotsky, J.M. (2003). Hepatitis C virus genetic variability: Pathogenic and clinical implications. Clin. Liver Dis. 7:45-66.
16. Piche, T., Gelsi, E., Schneider, S.M., Hebuterne, X., Giudicelli, J., Ferrua, B., Laffont, C., Benzaken, S., Hastier, P., Montoya, M.L., Longo, F., Rampal, P., and Tran, A. (2002). Fatigue is associated with high circulating leptin levels in chronic hepatitis C. Gut 51:434-439.
17. Poynard, T., Bedossa, P., and Opolon, P. (1997). Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349:825-832.
18. Poynard, T., Marcellin, P., Lee, S.S., Niederau, C., Minuk, G.S., Ideo, G., Bain, V., Heathcote, J., Zeuzem, S., Trepo, C., and Albrecht, J. (1998). Randomized trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352:1426-1432.
19. Rai, R., Wilson, L.E., Astemborski, J., Anania, F., Torbenson, M., Spoler, C., Vlahov, D., Strathdee, S.A., Boitnott, J., Nelson, K.E., and Thomas, D.L. (2002). Severity and correlates of liver disease in hepatitis C virus-infected injection drug users. Hepatology 35:1247-1255.
20. Rodger, A.J., Jolley, D., Thompson, S.C., Lanigan, A., and Crofts, N. (1999). The impact of diagnosis of hepatitis C virus on quality of life. Hepatology 30:1299-1301.
21. Rodger, A.J., Roberts, S., Lanigan, A., Bowden, S., Brown, T., and Crofts, N. (2000). Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975. Hepatology 32:582-587.
22. Seeff, L.B., Hollinger, F.B., Alter, H.J., Wright, E.C., Cain, C.M., Buskell, Z.J., Ishak, K.G., Iber, F.L., Toro, D., Samanta, A., Koretz, R.L., Perrillo, R.P., Goodman, Z.D., Knodell, R.G., Gitnick, G., Morgan, T.R., Schiff, E.R., Lasky, S., Stevens, C., Vlahcevic, R.Z., Weinshel, E., Tanwandee, T., Lin, H.J., and Barbosa, L. (2001). Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. Hepatology 33:455-463.
23. Seeff, L.B., Miller, R.N., Rabkin, C.S., Buskell-Bales, Z., Straley-Eason, K.D., Smoak, B.L., Johnson, L.D., Lee, S.R., and Kaplan, E.L. (2000). 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann. Intern. Med. 132:105-111.
24. Tillmann, H.L. (2001). Hepatitis C virus. N. Engl. J. Med. 345:1426.
25. Tillmann, H.L., Heiken, H., Knapik-Botor, A., Heringlake, S., Ockenga, J., Wilber, J.C., Goergen, B., Detmer, J., McMorrow, M., Stoll, M., Schmidt, R.E., and Manns, M.P. (2001). Infection with G.B. virus C and reduced mortality among HIV-infected patients. N. Engl. J. Med. 345:715-724.
26. Tillmann, H.L., Manns, M.P., Claes, C., Heiken, H., Schmidt, R.E., and Stoll, M. (in press). GB Virus C Infection and Quality of Life in HIV Positive Patients. AIDS Care: Psychol. Sociomed. Aspects AIDS/HIV.
27. Tong, M.J., El-Farra, N.S., Reikes, A.R., and Co, R.L. (1995). Clinical outcomes after transfusion-associated hepatitis C. N. Engl. J. Med. 332:1463-1466.
28. Vogt, M., Lang, T., Prosner, G., Klingler, C., Sendl, A.F., Zeller, A., Wiebecke, B., Langer, B., Meisner, H., and Hess, J. (1999). Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N. Engl. J. Med. 341:866-870.
29. Wiese, M., Berr, F., Lafrenz, M., Porst, H., and Oesen, U. (2000). Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in germany: A 20-year multicenter study. Hepatology 32:91-96.